Skillsoft

This company has attracted a ton of attention across Wall Street. Skillsoft Corp. (NYSE: SKIL) provides corporate digital learning services in the United States and internationally. Its enterprise learning solutions prepare organizations for the future of work, as well as enable them to overcome critical skill gaps, drive demonstrable behavior change and unlock the potential in their greatest assets.

Skillsoft provides a comprehensive suite of content, including a library of authorized technology and developer curricula and multiple learning modalities that dramatically increase learner engagement and retention.

The Colliers Securities target price is $13, and the consensus price target is $13.40. Skillsoft stock was last seen on Friday at $6.46 a share, up close to 4%.

SomaLogic

This stock was hit hard at the end of last year and looks to be clawing its way back. SomaLogic Inc. (NASDAQ: SLGC) operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow-off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein. It also offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples.

The company’s SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan’s biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness and others.

The company’s solutions also include SomaSignal tests, which are research use only tests for clinical trial applications. It serves research and clinical customers, with a focus on pharmaceutical and biotechnology companies, as well as academic research institutions. It also facilitates drug development, analysis of clinical trials and new human biology insights by assessing protein-protein and protein-gene networks.

Stifel recently started coverage and has a $12 target price. The consensus target is even higher at $16.25. The stock closed at $9.01 on Friday.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.